Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1324 participants.

Also called NCT07944261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,324 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07944261
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07944261. Randomized; single masking; primary purpose treatment. Start 2026-10-15 (actual); primary completion 2029-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits
Acronym
MILD-EFFECT
Condition
Acute Ischemic Stroke
Condition
Minor Ischemic Stroke
Intervention (Drug)
Tenecteplase 0.18 mg/kg
Intervention (Drug)
Tenecteplase 0.25 mg/kg
Lead sponsor
Shandong Provincial Hospital (class: other government)

Record details

Record id
cardio:ct-nct07944261
Content hash
a07a0ac47b4722f52a5bb80de48f1ea78c95c70c2aa4cf4709192772eaa17a51